澳大利亚ICU中免疫抑制患者病毒性严重急性呼吸道感染的全国性回顾性观察研究
该研究为澳大利亚46个ICU的全国性前瞻性登记数据库的回顾性分析(2022年6月至2025年8月),纳入实验室确诊病毒性SARI的成人(≥18岁)重症患者。免疫抑制定义为慢性免疫抑制、恶性肿瘤、AIDS/HIV或器官移植任一项。共4703例中免疫抑制者908例(19.3%),其年龄更大、合并症更多、COVID-19比例更高,接受抗病毒药和糖皮质激素更多,院内死亡率22.7% vs 13.1%。校正人口学、合并症、疫苗接种、ICU干预和治疗后,免疫抑制与院内死亡独立相关(aOR 1.93,95%CI 1.57-2.37)。
要点
- 免疫抑制状态是ICU病毒性SARI患者院内死亡的独立危险因素,校正后aOR 1.93(95%CI 1.57-2.37)。
- 免疫抑制患者占ICU病毒性SARI的19.3%(908/4703),院内死亡率22.7%,显著高于免疫正常者的13.1%。
- 免疫抑制患者更常因COVID-19入院(51.1% vs 34.5%),合并≥3种合并症比例更高(31.4% vs 22.5%)。
- 免疫抑制患者接受抗病毒药(67.3% vs 57.7%)和糖皮质激素(81.7% vs 72%)的比例均更高。
- 免疫抑制定义包含慢性免疫抑制、恶性肿瘤、AIDS/HIV或器官移植任一项。
适用人群与场景
- 澳大利亚46个ICU中年龄≥18岁、实验室确诊病毒性SARI的成人重症患者。
- 免疫抑制组定义为存在以下任一项:慢性免疫抑制、恶性肿瘤、AIDS/HIV、器官移植。
诊断标准与关键阈值
- 免疫抑制状态定义:慢性免疫抑制、恶性肿瘤、AIDS/HIV或器官移植任一项。
- 病毒性SARI需实验室确诊。
处置流程与药物剂量
- 原文未提及具体药物剂量、给药途径、频次或目标值。
- 原文仅报告治疗比例:免疫抑制组抗病毒药67.3%、糖皮质激素81.7%;免疫正常组分别为57.7%、72%。
红旗征与不能漏的情况
- 原文未提及具体红旗征或需立刻处理的情况。
研究设计与关键结果
- 研究类型:全国性前瞻性观察登记数据库的回顾性分析,46个ICU,2022年6月至2025年8月。
- 样本量:4703例病毒性SARI成人ICU患者,免疫抑制者908例(19.3%)。
- 主要终点:院内死亡率免疫抑制组22.7% vs 免疫正常组13.1%(p<0.01)。
- 校正人口学、合并症、疫苗接种状态(可得时)、ICU干预和治疗后,免疫抑制与院内死亡独立相关(aOR 1.93,95%CI 1.57-2.37)。
- 免疫抑制组年龄更大(中位67 vs 62岁),≥3种合并症更多(31.4% vs 22.5%),COVID-19更多(51.1% vs 34.5%),p<0.001。
- 采用Fine和Gray竞争风险模型评估免疫抑制与30天内出院风险的关联(原文未报告该结果的具体数值)。
证据类型、等级与局限
- 证据类型:回顾性观察性研究(基于前瞻性全国登记数据库)。
- 局限:回顾性分析;原文未提及其他局限。
对床旁实践的改变
- 对ICU病毒性SARI患者应识别免疫抑制状态(慢性免疫抑制、恶性肿瘤、AIDS/HIV、器官移植),因其院内死亡风险近翻倍。
- 免疫抑制患者更常因COVID-19入住ICU且合并症更多,床旁评估需关注这些特征。
- 原文建议对该人群考虑针对性公共卫生策略和改善治疗策略,但未给出具体方案。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The aim of this study was to compare the clinical characteristics, treatments and outcomes of immunocompromised patients with viral severe acute respiratory infections (SARI), to those of immunocompetent patients admitted to an intensive care unit (ICU) across Australia.
METHODS: Retrospective analysis of a prospective, nation-wide, observational registry of 46 ICUs from June 2022 to August 2025. Critically ill adults (age ≥ 18) with laboratory-confirmed viral SARI were included. Immunocompromised status was defined by the presence of any one of the following: chronic immunosuppression, malignant neoplasm, AIDS/HIV, or organ transplantation. Associations between immunocompromised status and in-hospital mortality were evaluated using mixed-effects logistic regression models. Competing risks regression (Fine and Gray models) was used to assess the association between immunocompromised status and risk of hospital discharge within 30 days.
RESULTS: Among 4,703 patients with viral SARI who were admitted to ICUs, immunocompromised patients accounted for 908 (19.3%) cases. Immunocompromised patients were older (median age 67 vs. 62 years), more comorbid (31.4% vs. 22.5% with ≥ 3 comorbidities), and more frequently admitted with COVID-19 (51.1% vs. 34.5%); (p < 0.001 for all). Immunocompromised patients received more treatment, including antivirals (67.3% vs. 57.7%), and corticosteroids (81.7% vs. 72%) and had higher in-hospital mortality (22.7% vs. 13.1%); (p < 0.01 for all). After adjusting for demographics, comorbidities, vaccination status (where available), ICU interventions and treatments, immunocompromised status was independently associated with nearly double the odds of in-hospital mortality (adjusted OR 1.93, 95% CI 1.57-2.37).
CONCLUSIONS: In this study, we found that immunocompromised patients accounted for approximately one-fifth of critically ill viral SARI patients and had nearly twice the odds of in-hospital mortality, when compared to those that were immunocompetent. Targeted public health campaigns and improved treatment strategies may be warranted for this population.
参考来源
- Hastak P, Andersen CR, Wah W, et al. Immunocompromised patients with viral severe acute respiratory infection in intensive care: an Australia wide, retrospective, observational study. Crit Care. 2026. PMID: 42469923. doi:10.1186/s13054-026-06192-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。